This study is a Phase 3, multicenter, randomized, double-blind, placebo- and active-controlled, parallel-group trial to evaluate the efficacy and safety of AXS-05 compared to placebo and bupropion for smoking cessation in adults.

开始日期2026-08-27

申办/合作机构

Axsome Therapeutics, Inc.

CTRI/2026/06/112419

/ Not yet recruitingN/AIIT

COMPARISON OF THE EFFICACY AND SAFETY OF DEXTROMETHORPHAN-BUPROPION AS AN ADD-ON THERAPY IN MAJOR DEPRESSIVE DISORDER. A RANDOMIZED, DOUBLE BLIND, PARALLEL-GROUP CONTROLLED TRIAL. - NIL

开始日期2026-07-01

申办/合作机构-

CTRI/2026/01/100712

/ Not yet recruitingN/AIIT

Prospective, Observational study on Efficacy and Safety of Dextromethorphan-Bupropion in Comparison to Desvenlafaxine in Patients with Major Depressive Disorder - nil

开始日期2026-01-20

申办/合作机构-

100 项与盐酸安非他酮/右美沙芬相关的临床结果

登录后查看更多信息

100 项与盐酸安非他酮/右美沙芬相关的转化医学

登录后查看更多信息

100 项与盐酸安非他酮/右美沙芬相关的专利（医药）

登录后查看更多信息

项与盐酸安非他酮/右美沙芬相关的文献（医药）

2026-04-13·EXPERT OPINION ON PHARMACOTHERAPY

Pharmacotherapeutic landscape for the management of agitation associated with Alzheimer’s disease

Review

作者: Tunc, Ece Buyuksandalyaci ; Grossberg, George T. ; Jain, Samir

INTRODUCTION:

Agitation associated with Alzheimer's disease (AAD) is common, persistent, and strongly linked to caregiver burden, emergency care, and institutionalization. Pharmacologic options have historically been limited by modest efficacy and safety liabilities in the geriatric population, creating a major treatment gap.

AREAS COVERED:

This narrative review summarizes established and emerging pharmacotherapies for AAD, emphasizing comparative efficacy, geriatric-relevant safety, and real-world feasibility. A literature search was conducted in PubMed/MEDLINE and ClinicalTrials.gov from database inception through 31 January 2026, prioritizing the most recent decade when applicable, and complemented these searches with hand searches of key trials, meta-analyses, guidelines, and publicly available regulatory or sponsor communications for late-stage programs. Evidence is synthesized qualitatively due to heterogeneity in definitions and outcomes. We discuss antipsychotics, serotonergic agents, drugs with negative trials, and pipeline approaches such as dextromethorphan-based combinations and adrenergic strategies.

EXPERT OPINION:

The field is shifting from broad off-label prescribing toward phenotype-informed, trial-validated treatments. Brexpiprazole establishes regulatory feasibility, while dextromethorphan-based combinations, particularly AXS-05, appear promising, including signals for durability. Progress will depend on harmonized outcomes, longer-term safety data, and pragmatic trials that prioritize function, caregiver impact, and crisis prevention.

2025-07-01·INDIAN JOURNAL OF PHARMACOLOGY

Efficacy and safety of dextromethorphan–bupropion combination (AXS-05) in the treatment of depression: A systematic review and network meta-analysis

Review

作者: S. Theepan Kumar ; Mohit Kumar Shahi ; JV Ashwin ; Astha Singh

This network meta-analysis evaluated the efficacy and safety of the dextromethorphan–bupropion combination (AXS-05) in treating major depressive disorder (MDD). Data were retrieved from multiple databases, including PubMed, Embase, Scopus, Google Scholar, and ClinicalKey, yielding 60 records. After removing duplicates and excluding irrelevant studies, such as reviews, case reports, posters, and studies focusing on unrelated populations (e.g., Alzheimer’s dementia), two randomized controlled trials (RCTs) – Tabuteau et al . (2022) and Iosifescu et al . (2022) – were selected for final analysis. The inclusion criteria focused on RCTs published between 2014 and 2024, involving adult participants (18–65 years) diagnosed with MDD, and reporting on the efficacy and safety of the dextromethorphan–bupropion combination. Studies that did not focus on MDD, were not in English, or lacked control groups were excluded. The findings indicate superior efficacy of the dextromethorphan–bupropion combination, with remission rates of 46.5% and 39.5%, compared to 16.2% for Bupropion alone and 17.3% for placebo. Despite a higher incidence of mild to moderate adverse events (72.9% vs. 64.6% for Bupropion), the combination’s safety profile remained comparable, with no significant increase in treatment discontinuation. These results suggest that AXS-05 is a promising treatment for MDD, warranting further investigation in larger, diverse populations to confirm its long-term efficacy and safety.

2024-11-01·CNS DRUGS

Glutamatergic Modulators for Major Depression from Theory to Clinical Use

Review

作者: Roger S. McIntyre ; Rakesh Jain

Major depressive disorder (MDD) is a chronic, burdensome, highly prevalent disease that is characterized by depressed mood and anhedonia. MDD is especially burdensome as approved monoamine antidepressant treatments have weeks-long delays before clinical benefit and low remission rates. In the past 2 decades, a promising target emerged to improve patient outcomes in depression treatment: glutamatergic signaling. This narrative review provides a high-level overview of glutamate signaling in synaptogenesis and neural plasticity and the implications of glutamate dysregulation in depression. Based on this preclinical evidence implicating glutamate in depression and the rapid improvement of depression with ketamine treatment in a proof-of-concept trial, a range of N-methyl-D-aspartate (NMDA)-targeted therapies have been investigated. While an array of treatments has been investigated in registered phase 2 or 3 clinical trials, the development of most of these agents has been discontinued. Multiple glutamate-targeted antidepressants are actively in development, and two are approved. Nasal administration of esketamine (Spravato^®) was approved by the US Food and Drug Administration (FDA) in 2019 to treat adults with treatment-resistant depression and in 2020 for adults with MDD with acute suicidal ideation or behavior. Oral combination dextromethorphan-bupropion (AXS-05, Auvelity^® extended-release tablet) was FDA approved in 2022 for the treatment of MDD in adults. These approvals bolster the importance of glutamate in depression and represent an exciting breakthrough in contemporary psychiatry, providing new avenues of treatment for patients as first-line therapy or with either poor response or unacceptable side effects to monoaminergic antidepressants.

357

项与盐酸安非他酮/右美沙芬相关的新闻（医药）

2026-09-07

·海上衣BIUBIUBIU

CNS这两周：亨廷顿病等到了第一个基因治疗，但Angelman又倒下一个ASO

这两周CNS领域信息量不小。罕见病拿到几个关键批件，也有一个III期意外折戟；发作性睡病赛道突然变得拥挤；还有一起挺值得琢磨的破产资产竞购。罕见病：进展居多，但也有一记重击 Ionis的Zanvastro拿到FDA批准，用于Alexander病。这是一种极罕见的儿童神经退行性疾病，患者基数很小，能走到获批，说明反义寡核苷酸平台在超罕见适应症上的商业化路径已经比较成熟了。 Acadia的DAYBU也拿到欧盟批准，用于雷特综合征(科普下，由X染色体基因突变导致的神经发育障碍性疾病）—这是Acadia在美国拿下同一适应症之后的又一次区域拓展。孤儿药"一个资产打多个地区"的打法越来越常见，本质上是用最小的临床增量换最大的地域覆盖。最重的一条是uniQure。AMT-130已经正式向FDA和英国递交了亨廷顿病基因治疗的上市申请，如果获批，会是全球首个亨廷顿病基因治疗药物，FDA审评节点定在2027年二季度。亨廷顿病此前基本是治疗空白，这一步一旦落地，会直接重新定义整个疾病的治疗范式。不过罕见病这条线不全是好消息。Ultragenyx的apazunersen在Angelman综合征的III期Aspire研究里，主要终点和关键次要终点全部没有达到。这个方向此前预期不低，ASO疗法在这个适应症上已经不是第一次受挫，这次失败会让整个赛道重新审视反义寡核苷酸能否真正逆转这类印记基因疾病的表型。精神神经：老药新用和难治性适应症在推进 Autobahn Therapeutics公布了elunetirom的非临床数据，显示它能促进突触连接和神经元能量代谢，为其抗抑郁机制提供了新的支持证据。 Axsome的AXS-05（也就是已获批用于抑郁症的Auvelity）启动了戒烟适应症的III期研究，完成了首例给药。这是典型的"老药新用"打法，用已验证的安全性数据，换一条低成本的适应症扩展路径。 Newron的evenamide在难治性精神分裂症的关键III期研究完成了入组筛选，主要数据readout定在2027年一季度，如果无所谓专利的话，值得持续跟踪。发作性睡病：突然拥挤的赛道这两周这个细分领域热闹得有点意外。Takeda的ORZEYFUL在日本拿到1型发作性睡病批准；Alkermes公布了alixorexton积极的II期数据，支持其正在推进的III期项目；再往前看，Nxera Pharma因为OX2R激动剂组合在后期临床取得进展，从Centessa那里拿到860万美元里程碑付款。三条线加在一起说明，食欲素受体2激动剂这个机制经过多年验证后，正从"单一玩家探索"变成"多家公司同台竞速"。对还在观望这个靶点的BD团队来说，窗口期可能没有想象中那么长了。诊断端：一条容易被忽略但影响更深远的消息罗氏的Elecsys pTau217血液检测拿到FDA批准，用于阿尔茨海默病评估。血液生物标志物检测如果能大规模替代PET影像和脑脊液穿刺，会直接改变AD药物临床开发的入组效率，以及真实世界的早筛路径。这对所有在做AD疗法的公司——不管是抗Aβ还是抗tau方向——都是基础设施层面的利好。融资并购：困境资产里藏着机会最值得说的是BioXcel Therapeutics申请破产，Teva随后以最高1.25亿美元竞标其神经科学资产。这是典型的困境资产收购：BioXcel手里的资产临床数据和获批状态都还在，只是商业化不及预期导致现金流断裂。对愿意接盘的买家来说，破产程序里的资产往往能拿到比正常BD谈判更有利的估值，尤其适合手里有余粮、想低成本切入美国神经科学商业化渠道的买家。另外两笔融资也值得记一笔：Werewolf Therapeutics和Ambros Therapeutics宣布合并，同步完成1.5亿美元融资，把Neridronate推进到III期治疗CRPS-1（复杂区域疼痛综合征）；NovaGo Therapeutics完成3000万美元B轮，把抗Nogo-A生物制剂推进到急性脊髓损伤的概念验证阶段。两笔钱都指向同一个逻辑：投资人对CNS里"机制明确、患者定义清晰"的细分适应症仍然愿意买单，哪怕大盘对CNS整体估值偏保守。这两周的信息密度，其实体现出几个清晰的分层：超罕见病和基因治疗还在稳步兑现监管里程碑；反义寡核苷酸在复杂神经发育疾病上的失败率依然不低；发作性睡病这类机制相对成熟的赛道已经进入多头竞争；诊断工具的进步，可能比单一药物获批对整个AD领域的影响更长远。对国内做CNS方向BD筛选的团队来说，短期比较值得优先关注的，还是OX2R激动剂这类已经有多方数据验证、机制风险相对较低的资产，以及像BioXcel这样处于困境重组、估值可能被错杀的标的。

孤儿药寡核苷酸临床3期引进/卖出基因疗法

2026-09-02

·GlobeNewswire-Health Care

Axsome Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in the following upcoming investor conferences in September: Wells Fargo 21st Annual Healthcare Conference Fireside Chat: Wednesday, September 9, 2026, at 3:45 p.m. ET in Boston, MA 2026 Cantor Global Healthcare Conference Fireside Chat: Thursday, September 10, 2026, at 2:45 p.m. ET in New York, NY Morgan Stanley 24th Annual Global Healthcare Conference Fireside Chat: Monday, September 14, 2026, at 1:50 p.m. ET in New York, NY Baird 2026 Global Healthcare Conference Fireside Chat: Tuesday, September 15, 2026, at 2:35 p.m. ET in New York, NY H.C. Wainwright 28th Annual Global Investment Conference Presentation: Wednesday, September 16, 2026, at 10:00 a.m. ET in New York, NY Deutsche Bank 2026 Healthcare Summit Investor Meetings: Thursday, September 17, 2026, in New York, NY Live webcasts of the Wells Fargo, Cantor, H.C. Wainwright, and Morgan Stanley sessions can be accessed on the “Webcasts & Presentations” page of the “Investors” section of the Company’s website at axsome.com. Replays of the webcasts will be available for approximately 30 days following each event. About Axsome Therapeutics Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, agitation associated with dementia due to Alzheimer’s disease, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, as well as multiple novel product candidates addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain’s biggest problems so patients and their loved ones can flourish. For more information, please visit us at www.axsome.com and follow us on LinkedIn and X. Forward Looking Statements Certain matters discussed in this press release are “forward-looking statements”. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of the Company’s SUNOSI®, AUVELITY®, and SYMBRAVO® products and the success of the Company’s efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the Company’s ability to maintain and expand payer coverage; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund the Company’s disclosed clinical trials, which assumes no material changes to the Company’s currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of the Company’s current product candidates; the Company’s ability to fund additional clinical trials to continue the advancement of the Company’s product candidates; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, the Company’s product candidates, including statements regarding the timing of any NDA submission; the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the Company’s ability to successfully resolve any intellectual property litigation, and even if such disputes are settled, whether the applicable federal agencies will approve of such settlements; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s products and product candidates, if approved; the Company’s anticipated capital requirements, including the amount of capital required for the commercialization of SUNOSI, AUVELITY, and SYMBRAVO and for the Company’s commercial launch of its other product candidates, if approved, and the potential impact on the Company’s anticipated cash runway; the Company’s ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. Investors:Ashley DongSenior Director, Investor Relations(929) 687-1614adong@axsome.com Media:Darren OplandSenior Director, Corporate Communications(929) 837-1065 dopland@axsome.com

2026-09-02

·BioSpace

Axsome Therapeutics to Participate in Upcoming September 2026 Investor Conferences

NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in the following upcoming investor conferences in September: Wells Fargo 21 st Annual Healthcare Conference Fireside Chat: Wednesday, September 9, 2026, at 3:45 p.m. ET in Boston, MA 2026 Cantor Global Healthcare Conference Fireside Chat: Thursday, September 10, 2026, at 2:45 p.m. ET in New York, NY Morgan Stanley 24th Annual Global Healthcare Conference Fireside Chat: Monday, September 14, 2026, at 1:50 p.m. ET in New York, NY Baird 2026 Global Healthcare Conference Fireside Chat: Tuesday, September 15, 2026, at 2:35 p.m. ET in New York, NY H.C. Wainwright 28th Annual Global Investment Conference Presentation: Wednesday, September 16, 2026, at 10:00 a.m. ET in New York, NY Deutsche Bank 2026 Healthcare Summit Investor Meetings: Thursday, September 17, 2026, in New York, NY Live webcasts of the Wells Fargo, Cantor, H.C. Wainwright, and Morgan Stanley sessions can be accessed on the “Webcasts & Presentations” page of the “Investors” section of the Company’s website at axsome.com. Replays of the webcasts will be available for approximately 30 days following each event. About Axsome Therapeutics Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, agitation associated with dementia due to Alzheimer’s disease, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, as well as multiple novel product candidates addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain’s biggest problems so patients and their loved ones can flourish. For more information, please visit us at and follow us on LinkedIn and X . ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); Forward Looking Statements Certain matters discussed in this press release are “forward-looking statements”. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of the Company’s SUNOSI ® , AUVELITY ® , and SYMBRAVO ® products and the success of the Company’s efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the Company’s ability to maintain and expand payer coverage; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund the Company’s disclosed clinical trials, which assumes no material changes to the Company’s currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of the Company’s current product candidates; the Company’s ability to fund additional clinical trials to continue the advancement of the Company’s product candidates; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, the Company’s product candidates, including statements regarding the timing of any NDA submission; the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the Company’s ability to successfully resolve any intellectual property litigation, and even if such disputes are settled, whether the applicable federal agencies will approve of such settlements; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s products and product candidates, if approved; the Company’s anticipated capital requirements, including the amount of capital required for the commercialization of SUNOSI, AUVELITY, and SYMBRAVO and for the Company’s commercial launch of its other product candidates, if approved, and the potential impact on the Company’s anticipated cash runway; the Company’s ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. Investors: Ashley Dong Senior Director, Investor Relations (929) 687-1614 adong@axsome.com Media: Darren Opland Senior Director, Corporate Communications (929) 837-1065 dopland@axsome.com ezstandalone.cmd.push(function () { ezstandalone.showAds(132); });

100 项与盐酸安非他酮/右美沙芬相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D12493	盐酸安非他酮/右美沙芬	-	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
阿尔茨海默症	美国	Axsome Therapeutics, Inc.	2026-04-30
痴呆	美国	Axsome Therapeutics, Inc.	2026-04-30
重度抑郁症	美国	Axsome Therapeutics, Inc.	2022-08-18

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
痴呆引起的激越	申请上市	美国	Axsome Therapeutics, Inc.	2025-12-31
尼古丁成瘾	临床3期	美国	Axsome Therapeutics, Inc.	2026-08-27
阿尔茨海默病引起的痴呆症	临床3期	澳大利亚	Axsome Therapeutics, Inc.	2017-07-13
精神运动性激动	临床3期	澳大利亚	Axsome Therapeutics, Inc.	2017-07-13
难治性抑郁症	临床3期	美国	Axsome Therapeutics, Inc.	2016-03-01
尼古丁依赖	临床2期	美国	Axsome Therapeutics, Inc.	2018-03-25

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05976646 (CTgov)	临床1/2期	阿片滥用	18	Placebo (Placebo)	艱夢積網製遞窪製醖觸(餘膚衊醖淵顧襯餘簾廠) = 鏇製夢膚齋觸製顧築繭鑰艱構襯鏇繭簾鹹餘襯 (憲顧廠夢鹽遞願淵鹽顧, 16.53) 更多	-	2026-08-19
				Auvelity (Auvelity)	艱夢積網製遞窪製醖觸(餘膚衊醖淵顧襯餘簾廠) = 觸繭構鑰獵壓鏇觸淵選鑰艱構襯鏇繭簾鹹餘襯 (憲顧廠夢鹽遞願淵鹽顧, 7.90) 更多
NCT05557409 (ADVANCE-2, CTgov)	临床3期	阿尔茨海默症 \| 痴呆引起的激越	408	AXS-05 (AXS-05)	廠繭製鹹蓋願窪膚鑰選(壓憲壓鏇夢遞齋獵醖觸) = 餘鏇繭窪窪網願艱範構艱鬱膚蓋廠積餘網簾網 (鑰壓鬱糧遞蓋選製築遞, 0.917) 更多	-	2026-08-13
				Placebo (Placebo)	廠繭製鹹蓋願窪膚鑰選(壓憲壓鏇夢遞齋獵醖觸) = 獵簾壓膚齋膚顧膚製觸艱鬱膚蓋廠積餘網簾網 (鑰壓鬱糧遞蓋選製築遞, 0.921) 更多
NCT06736509 (CTgov)	临床3期	痴呆引起的激越 \| 精神运动性激动 \| 阿尔茨海默病引起的痴呆症	139	AXS-05 (dextromethorphan-bupropion)	鹹網齋築膚簾鏇繭鏇鏇 = 淵壓鹽夢艱醖憲憲築醖鏇簾蓋夢壓鹽夢齋餘淵 (憲鹹範鹹齋醖願鹽築簾, 夢範簾糧糧鏇繭廠壓願 ~ 壓鏇簾鬱艱醖鹹鏇齋壓) 更多	-	2026-06-25
NCT04634669 (CTgov)	临床2期	重度抑郁症 \| 难治性抑郁症	181	AXS-05	壓淵獵淵淵淵鏇願網構 = 壓醖憲淵網範艱選艱積顧醖製蓋繭餘繭簾顧壓 (餘淵糧憲築製繭齋鹽蓋, 築構餘鹹遞遞鹹願鏇衊 ~ 製鏇獵壓廠構遞網醖選) 更多	-	2026-01-28
NCT04947553 (ACCORD-2, Company_Website) 人工标引	临床3期	阿尔茨海默症 \| 躁动	167	AXS-05	膚艱壓淵遞壓觸製壓鑰(齋襯憲構窪鹹範齋鬱窪): HR = 0.276, P-Value = 0.001 达到更多	积极	2024-12-30
				Placebo
NCT05557409 (ADVANCE-2, Company_Website) 人工标引	临床3期	阿尔茨海默症 \| 躁动	408	AXS-05	觸膚淵壓鑰膚觸簾憲膚(蓋衊醖願範糧糧鬱艱壓) = 醖構築製餘壓餘糧範構鑰衊選鏇願範積淵夢餘 (繭醖繭齋衊選糧選淵積 ) 未达到更多	不佳	2024-12-30
				Placebo	觸膚淵壓鑰膚觸簾憲膚(蓋衊醖願範糧糧鬱艱壓) = 遞觸壓遞膚廠觸觸夢蓋鑰衊選鏇願範積淵夢餘 (繭醖繭齋衊選糧選淵積 ) 未达到更多
AAN2024	N/A	痴呆引起的激越	-	AXS-05	積繭窪襯醖艱夢構窪鬱(鹽夢膚廠鬱襯餘膚淵艱) = Overall adverse event rates in the DBP were 28.3% AXS-05, 22.2% placebo 網艱鬱衊餘簾鏇鏇繭淵 (齋鹽憲蓋鏇膚餘積憲獵 ) 更多	-	2024-04-09
				Placebo
NCT04797715 (ACCORD, CTAD2023)	临床3期	阿尔茨海默症	108	AXS-05	遞獵簾鹹鏇醖築構範簾(窪築構願遞艱簾獵淵夢) = 襯遞鹽願窪網願夢壓蓋網簾獵窪壓積廠憲夢選 (選廠鹽繭壓醖鹽蓋壓鏇 ) 更多	积极	2023-10-24
				Placebo	遞獵簾鹹鏇醖築構範簾(窪築構願遞艱簾獵淵夢) = 襯夢製淵鏇築壓餘壓鑰網簾獵窪壓積廠憲夢選 (選廠鹽繭壓醖鹽蓋壓鏇 ) 更多
NCT03226522 (ADVANCE, CTgov)	临床2/3期	痴呆引起的激越 \| 精神运动性激动 \| 阿尔茨海默病引起的痴呆症	366	AXS-05 (AXS-05)	餘衊餘製製衊獵選衊醖(簾選餘壓窪積窪獵構選) = 艱膚餘簾繭衊襯壓繭獵顧遞糧遞簾廠選範積壓 (顧簾築憲襯簾憲壓襯窪, 1.25) 更多	-	2023-09-13
				Bupropion (Bupropion)	餘衊餘製製衊獵選衊醖(簾選餘壓窪積窪獵構選) = 醖鏇構鹹餘顧鑰蓋範蓋顧遞糧遞簾廠選範積壓 (顧簾築憲襯簾憲壓襯窪, 3.02) 更多
EVOLVE (Corporate Publications) 人工标引	N/A	抑郁症	186	AXS-05	壓繭鬱網衊淵憲餘糧網(選鏇壓壓淵糧窪鹹顧構) = 製醖構膚齋糧糧網窪製壓鬱襯艱蓋壓顧繭願壓 (願獵艱鏇鏇鬱壓蓋繭鑰, 6.33) 更多	积极	2022-12-07